# China NMPA Inspection - Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd. - August 24, 2018

Source: https://www.globalkeysolutions.net/records/china_inspection/qinghai-xinlvzhou-pharmaceutical-group-co-ltd/50129642-e90f-49d8-81ee-c57a1672f23b/
Source feed: China

> China NMPA unannounced inspection for Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd. published August 24, 2018. The National Medical Products Administration (NMPA) issued a formal notification regarding an unannounced inspection conducted at the Datong Drug Dist

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Notification of Unannounced Inspection of Datong Drug Distribution Center of Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd.
- Company Name: Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd.
- Publication Date: 2018-08-24
- Product Type: drugs
- Summary: The National Medical Products Administration (NMPA) issued a formal notification regarding an unannounced inspection conducted at the Datong Drug Distribution Center, a key facility belonging to Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd. This critical regulatory communication, specifically titled "Notification of Unannounced Inspection of Datong Drug Distribution Center of Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd.," was officially published on August 24, 2018. This publication date signifies that the inspection itself had already taken place sometime before this announcement. Operating within the stringent regulatory framework of the NMPA, which oversees drug administration and pharmaceutical compliance in China, this notification underscores the agency's commitment to ensuring the integrity and safety of the national drug supply chain. Unannounced inspections are a standard tool used by regulatory bodies to assess ongoing compliance and operational standards. However, the provided document is strictly limited to announcing the occurrence of this inspection event. It does not elaborate on specific dates when the inspection was carried out, nor does it detail any particular violations, non-compliance issues, or deficiencies that might have been identified during the review. Consequently, the document also refrains from outlining any specific required corrective actions or enforcement measures for Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd. The notification primarily serves as an official public record of the NMPA's regulatory oversight activity, made accessible through its official website and related platforms like the China Drug Administration App, ensuring transparency in its enforcement efforts.

Company: https://www.globalkeysolutions.net/companies/qinghai-xinlvzhou-pharmaceutical-group-co-ltd/a7e60e8e-db3c-43a0-b0b1-c9f22f9e5f4a/